Navigation Links
New England Biolabs Expands its Distribution Network through Collaborations in India and the Netherlands
Date:4/12/2011

IPSWICH, Mass., April 12, 2011 /PRNewswire/ -- New England Biolabs (NEB), a world leader in the production and supply of reagents for life science research, announces that it has signed exclusive distribution agreements with BIOKE, based in the Netherlands, and Imperial Life Sciences (ILS), based in India.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

BIOKE, a Cell Signaling Technology (CST) Europe BV company, is located in Leiden, the Netherlands, and serves Belgium, the Netherlands and Luxemborg. BIOKE supplies reagents for signal transduction, cell culture, molecular biology and laboratory equipment. ILS is a biosupplier company based in Gurgaon, India that currently supplies reagents and instrumentation for genomics, proteomics, cell biology and imaging. By signing agreements in these two regions, NEB's distribution network now extends to 39 companies worldwide.

"NEB maintains an extensive global distribution network to afford our customers efficient access to our high quality reagents throughout the world," states Dr. Peter Nathan, Director of Global Business Development at NEB. "Collaborations with companies such as BIOKE and ILS further strengthen our ability to support the needs of our customers, through their service capabilities, including both ease-of-procurement and excellent technical support."

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications, and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs, visit www.neb.com.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. River Valley Community College and Medical Messenger Team Up to Prepare the Future Nurses of New England
2. Technology Collaboration Between New England Biolabs and Sequenom Delivers First Product for Epigenetics
3. Hospitalists at New England Baptist Hospital Choose MedAptus
4. New England Biolabs Releases JoVE Video Protocol Highlighting Assay to Quantitate 5-hmC in Epigenome
5. New England Patriots Offensive Line Wins Second Annual Madden Most Valuable Protectors Award Presented by Prilosec OTC®
6. Pescatello Elected to Head New England Biotech Association in 2011-12
7. Positive Phase II Results with Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine
8. Study Published in New England Journal of Medicine Shows Nplate® Significantly Reduces Treatment Failure and Splenectomy Rate in Patients With Chronic ITP
9. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
10. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
11. New England Biolabs Receives Award to Develop Novel Enzymatic Reagents for Epigenetic Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... 20, 2017  CVS Pharmacy, the retail division ... new store design to enhance the retail customer ... health-focused products and expanded beauty selections paired with ... discover new offerings. Together with its innovative digital ... the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology:
(Date:4/26/2017)... , ... April 26, 2017 , ... RawTrition now brings ... way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients to ... cellular level because the body recognizes its raw form (unlike the synthetically made options ...
(Date:4/26/2017)... ... April 26, 2017 , ... MYOLYN, ... to announce that it has received 510(k) clearance from the U.S. Food & ... the MyoCycle Pro. , Both devices are stationary cycling systems that use MYOLYN’s ...
(Date:4/25/2017)... ... April 25, 2017 , ... Coalition Duchenne, ... Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor Therapeutics on ... clinical trial in Duchenne announced today. , Coalition Duchenne funded studies carried ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
Breaking Medicine News(10 mins):